- Home
- OMER vs MLR Comparison
OMER vs MLR Comparison
Compare OMER & MLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- MLR
- Stock Information
- Founded
- OMER 1994
- MLR 1990
- Country
- OMER United States
- MLR United States
- Employees
- OMER N/A
- MLR N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- MLR Construction/Ag Equipment/Trucks
- Sector
- OMER Health Care
- MLR Consumer Discretionary
- Exchange
- OMER Nasdaq
- MLR Nasdaq
- Market Cap
- OMER 397.1M
- MLR 455.2M
- IPO Year
- OMER 2009
- MLR 1994
- Fundamental
- Price
- OMER $3.22
- MLR $46.33
- Analyst Decision
- OMER Buy
- MLR Strong Buy
- Analyst Count
- OMER 4
- MLR 1
- Target Price
- OMER $22.50
- MLR $82.00
- AVG Volume (30 Days)
- OMER 1.2M
- MLR 65.6K
- Earning Date
- OMER 05-15-2025
- MLR 05-07-2025
- Dividend Yield
- OMER N/A
- MLR 1.72%
- EPS Growth
- OMER N/A
- MLR N/A
- EPS
- OMER N/A
- MLR 4.69
- Revenue
- OMER N/A
- MLR $1,133,280,000.00
- Revenue This Year
- OMER N/A
- MLR N/A
- Revenue Next Year
- OMER $2,447.88
- MLR $18.55
- P/E Ratio
- OMER N/A
- MLR $9.81
- Revenue Growth
- OMER N/A
- MLR N/A
- 52 Week Low
- OMER $3.00
- MLR $37.40
- 52 Week High
- OMER $13.60
- MLR $78.25
- Technical
- Relative Strength Index (RSI)
- OMER 23.29
- MLR 62.29
- Support Level
- OMER $3.79
- MLR $45.83
- Resistance Level
- OMER $6.58
- MLR $47.73
- Average True Range (ATR)
- OMER 0.59
- MLR 1.16
- MACD
- OMER -0.33
- MLR 0.66
- Stochastic Oscillator
- OMER 5.43
- MLR 82.26
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About MLR Miller Industries Inc.
Miller Industries Inc is engaged in the manufacturing of vehicle towing and recovery equipment. The company produces wreckers, car carriers, and trailer bodies under the Century, Vulcan, Challenger, Holmes, Champion, Chevron, Eagle, Titan, Jige, and Boniface brands. The products are sold in North America, Canada, and Mexico through independent distributors.